These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37018145)

  • 1. Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis.
    Sangha K; Chang ST; Cheung R; Deshpande VS
    Hepatology; 2023 May; 77(5):1702-1711. PubMed ID: 37018145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost Effectiveness of Different Strategies for Detecting Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Based on United States Health Care System.
    Vilar-Gomez E; Lou Z; Kong N; Vuppalanchi R; Imperiale TF; Chalasani N
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2305-2314.e12. PubMed ID: 32289535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.
    Tapper EB; Sengupta N; Hunink MG; Afdhal NH; Lai M
    Am J Gastroenterol; 2015 Sep; 110(9):1298-304. PubMed ID: 26303130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis.
    Chon YE; Jin YJ; An J; Kim HY; Choi M; Jun DW; Kim MN; Han JW; Lee HA; Yu JH; Kim SU
    Clin Mol Hepatol; 2024 Sep; 30(Suppl):S117-S133. PubMed ID: 39165159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
    Tapper EB; Hunink MG; Afdhal NH; Lai M; Sengupta N
    PLoS One; 2016; 11(2):e0147237. PubMed ID: 26905872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Imajo K; Honda Y; Kobayashi T; Nagai K; Ozaki A; Iwaki M; Kessoku T; Ogawa Y; Takahashi H; Saigusa Y; Yoneda M; Kirikoshi H; Utsunomiya D; Aishima S; Saito S; Nakajima A
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):908-917.e11. PubMed ID: 33340780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.
    Bresnahan R; Duarte R; Mahon J; Beale S; Chaplin M; Bhattacharyya D; Houten R; Edwards K; Nevitt S; Maden M; Boland A
    Health Technol Assess; 2023 Jul; 27(10):1-115. PubMed ID: 37839810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
    Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
    J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis.
    Choo BP; Goh GBB; Chia SY; Oh HC; Tan NC; Tan JYL; Ang TL; Bee YM; Wong YJ
    Ann Acad Med Singap; 2022 Nov; 51(11):686-694. PubMed ID: 36453216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
    Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
    J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness study of FIB-4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at-risk population.
    Park H; Yoon EL; Kim M; Kwon SH; Kim D; Cheung R; Kim HL; Jun DW
    Liver Int; 2024 Apr; 44(4):944-954. PubMed ID: 38291809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of nonalcoholic steatohepatitis screening.
    Zhang E; Wartelle-Bladou C; Lepanto L; Lachaine J; Cloutier G; Tang A
    Eur Radiol; 2015 Nov; 25(11):3282-94. PubMed ID: 25994191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis.
    Singh S; Venkatesh SK; Loomba R; Wang Z; Sirlin C; Chen J; Yin M; Miller FH; Low RN; Hassanein T; Godfrey EM; Asbach P; Murad MH; Lomas DJ; Talwalkar JA; Ehman RL
    Eur Radiol; 2016 May; 26(5):1431-40. PubMed ID: 26314479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
    J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient Versus Two-Dimensional Shear-Wave Elastography in a Multistep Strategy to Detect Advanced Fibrosis in NAFLD.
    Cassinotto C; Boursier J; Paisant A; Guiu B; Irles-Depe M; Canivet C; Aube C; de Ledinghen V
    Hepatology; 2021 Jun; 73(6):2196-2205. PubMed ID: 33236409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants.
    Hsu C; Caussy C; Imajo K; Chen J; Singh S; Kaulback K; Le MD; Hooker J; Tu X; Bettencourt R; Yin M; Sirlin CB; Ehman RL; Nakajima A; Loomba R
    Clin Gastroenterol Hepatol; 2019 Mar; 17(4):630-637.e8. PubMed ID: 29908362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD.
    Nogami A; Yoneda M; Iwaki M; Kobayashi T; Kessoku T; Honda Y; Ogawa Y; Imajo K; Higurashi T; Hosono K; Kirikoshi H; Saito S; Nakajima A
    Sci Rep; 2022 Dec; 12(1):21925. PubMed ID: 36535977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.